Pharmaceuticals, Biotechnology and Life Sciences
Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium
WASHINGTON–(BUSINESS WIRE)–#Medicare–Today, Citizens Against Government Waste (CAGW) released the following comments regarding House Speaker Nancy Pelosi’s (D-Calif.) partisan drug pricing…
Apristor, an oral progesterone receptor antagonist, is being studied in combination with an antiestrogen in advanced ER+,PR+,HER2- endometrial cancer Study…
Tetra Therapeutics has surpassed 50% enrollment – 65% of which are Hispanic patients– in its Phase 2 clinical trial (PICASSO…
DEERFIELD, Ill.–(BUSINESS WIRE)–Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fourth quarter and fiscal 2019 earnings results at 7…
Aerie Pharmaceuticals has submitted a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA), to be allowed to produce Rocklatan in Ireland, to be sold USA.
Lineage Cell Therapeutic’s comparative clinical trial met its primary endpoint of change in hemifacial volume at six months (p<.001), which…
Takeda has been named in the Dow Jones Sustainabilitz World Index, having more than double the average overall industry score, the company said in a press release Wednesday, noting it was also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year.
Nanobiotix’s radioenhancer NBTXR3 study showed encouraging results for Hepatocellular Carcinoma (HCC) patients, which are significant as they increase the scope of patients NBTXR3 may treat beyond Soft Tissue Sarcoma and Head and Neck cancer.
Transgene has posted net loss amounted to €15.3 million for the first half of 2019 compared to €14.9 million for the same period in 2018, while its cash, cash equivalents and other financial assets amounted to €12.8 million versus €16.9 million as of December 31, 2018.